Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BVNRY
Previous Symbol
CUSIPN/A
Phone45-3326-8383
Debt
Debt-to-Equity Ratio0.18
Current Ratio5.35
Quick Ratio5.07
Price-To-Earnings
Trailing P/E Ratio24.10
Forward P/E Ratio-12.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$208.06 million
Price / Sales3.26
Cash Flow$0.3460 per share
Price / Cash Flow20.20
Book Value$3.96 per share
Price / Book1.77
Profitability
EPS (Most Recent Fiscal Year)$0.29
Net Income$27.54 million
Net Margins-126.80%
Return on Equity-19.17%
Return on Assets-14.54%
Miscellaneous
Employees420
Outstanding Shares96,930,000
Market Cap$677.54 million
OptionableNot Optionable
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions
What is BAVARIAN NORDIC/S's stock symbol?
BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY."
How were BAVARIAN NORDIC/S's earnings last quarter?
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) announced its quarterly earnings data on Friday, November, 9th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.14) by $0.19. The firm had revenue of $34.58 million for the quarter. BAVARIAN NORDIC/S had a negative return on equity of 19.17% and a negative net margin of 126.80%. View BAVARIAN NORDIC/S's Earnings History.
When is BAVARIAN NORDIC/S's next earnings date?
Has BAVARIAN NORDIC/S been receiving favorable news coverage?
News stories about BVNRY stock have trended somewhat positive on Saturday, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BAVARIAN NORDIC/S earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Who are some of BAVARIAN NORDIC/S's key competitors?
Some companies that are related to BAVARIAN NORDIC/S include Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Spark Therapeutics (ONCE), Editas Medicine (EDIT), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Autolus Therapeutics (AUTL) and Iovance Biotherapeutics (IOVA).
Who are BAVARIAN NORDIC/S's key executives?
BAVARIAN NORDIC/S's management team includes the folowing people:
- Dr. Paul Chaplin, CEO & Pres (Age 51)
- Mr. Henrik Juuel, CFO & Exec. VP (Age 53)
- Mr. Henrik Birk, COO & Exec. VP (Age 44)
- Dr. Christopher R. Heery M.D., Chief Medical Officer
- Dr. Tommi Kainu M.D., Ph.D., Exec. VP, Chief Bus. Officer & Member of the Exec. Management (Age 45)
How do I buy shares of BAVARIAN NORDIC/S?
Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BAVARIAN NORDIC/S's stock price today?
One share of BVNRY stock can currently be purchased for approximately $6.99.
How big of a company is BAVARIAN NORDIC/S?
BAVARIAN NORDIC/S has a market capitalization of $677.54 million and generates $208.06 million in revenue each year. The company earns $27.54 million in net income (profit) each year or $0.29 on an earnings per share basis. BAVARIAN NORDIC/S employs 420 workers across the globe.
What is BAVARIAN NORDIC/S's official website?
How can I contact BAVARIAN NORDIC/S?
BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected]
MarketBeat Community Rating for BAVARIAN NORDIC/S (OTCMKTS BVNRY)
MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC/S and other stocks. Vote "Outperform" if you believe BVNRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVNRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
